Home / Journals / OR / Vol.28, No.2, 2020
  • Open Access

    ARTICLE

    Pathway Mutations in Breast Cancer Using Whole-Exome Sequencing

    Ya-Sian Chang*†‡§, Chieh-Min Chang†‡, Chien-Yu Lin¶#, Dy-San Chao, Hsi-Yuan Huang, Jan-Gowth Chang*†‡**††
    Oncology Research, Vol.28, No.2, pp. 107-116, 2020, DOI:10.3727/096504019X15698362825407
    Abstract The genomic landscape of breast cancer (BC) is complex. The purpose of this study was to decipher the mutational profiles of Taiwanese patients with BC using next-generation sequencing. We performed whole-exome sequencing on DNA from 24 tumor tissue specimens from BC patients. Sanger sequencing was used to validate the identified variants. Sanger sequencing was also performed on paired adjacent nontumor tissues. After genotype calling and algorithmic annotations, we identified 49 deleterious variants in canonical cancer-related genes in our BC cohort. The most frequently mutated genes were PIK3CA (16.67%), FKBP9 (12.5%), TP53 (12.5%), ATM (8.33%), CHEK2 (8.33%), FOXO3 (8.33%), NTRK1More >

  • Open Access

    ARTICLE

    Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

    Xiuhua Weng*1, Shaohong Luo*1, Shen Lin*, Lixian Zhong, Meiyue Li*, Rao Xin*, Pinfang Huang*, Xiongwei Xu*
    Oncology Research, Vol.28, No.2, pp. 117-125, 2020, DOI:10.3727/096504019X15707883083132
    Abstract To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE- 042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were computed… More >

  • Open Access

    ARTICLE

    Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases

    Jianping Xu, Xiaoyan Liu, Sheng Yang, Yuankai Shi
    Oncology Research, Vol.28, No.2, pp. 127-133, 2020, DOI:10.3727/096504019X15707896762251
    Abstract Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib (250 mg or 500 mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy… More >

  • Open Access

    ARTICLE WITHDRAWN

    [ARTICLE WITHDRAWN] Long Noncoding RNA KCNQ1OT1 Accelerates the Progression of Ovarian Cancer via MicroRNA-212-3/LCN2 Axis

    Lu, Xiaoqin1, Wang, Fuying1, Fu, Meizhou2, Li, Yuankun1, Wang, Lijun1
    Oncology Research, Vol.28, No.2, pp. 135-146, 2020, DOI:10.3727/096504019X15719983040135
    Abstract This article was wihdrawn by the authors with the following Withdrawal Statement - The integrity of the current study is not acceptable. The authors intend to enrich the study to make it more valuable. Thus, the authors want to withdraw the current study. Please accept our apologies for this inconvenience and we hope for your understanding. Yours sincerely (on behalf of the authors), Xiaoqin Lu. More >

  • Open Access

    ARTICLE

    MicroRNA-561 Affects Proliferation and Cell Cycle Transition Through PTEN/AKT Signaling Pathway by Targeting P-REX2a in NSCLC

    ZiJun Liao*†, Qi Zheng, Ting Wei, YanBing Zhang, JieQun Ma, Zheng Zhao§, HaiFeng Sun§, KeJun Nan*
    Oncology Research, Vol.28, No.2, pp. 147-159, 2020, DOI:10.3727/096504019X15732109856009
    Abstract MicroRNAs (miRNAs) play crucial roles in tumorigenesis and tumor progression. miR-561 has been reported to be downregulated in gastric cancer and affects cancer cell proliferation and metastasis. However, the role and underlying molecular mechanism of miR-561 in human non-small cell lung cancer (NSCLC) remain unknown and need to be further elucidated. In this study, we discovered that miR-561 expression was downregulated in human NSCLC tissues and cell lines. The overexpression of miR-561 inhibited NSCLC cell proliferation and cell cycle G1 /S transition and induced apoptosis. The inhibition of miR-561 facilitated cell proliferation and G1 /S transition and suppressed apoptosis. miR-561… More >

  • Open Access

    ARTICLE

    Enhancement of Radiosensitivity by Eurycomalactone in Human NSCLC Cells Through G2 /M Cell Cycle Arrest and Delayed DNA Double-Strand Break Repair

    Nahathai Dukaew*†, Teruaki Konishi‡§, Kongthawat Chairatvit, Narongchai Autsavapromporn#, Noppamas Soonthornchareonnon**, Ariyaphong Wongnoppavich
    Oncology Research, Vol.28, No.2, pp. 161-175, 2020, DOI:10.3727/096504019X15736439848765
    Abstract Radiotherapy (RT) is an important treatment for non-small cell lung cancer (NSCLC). However, the major obstacles to successful RT include the low radiosensitivity of cancer cells and the restricted radiation dose, which is given without damaging normal tissues. Therefore, the sensitizer that increases RT efficacy without dose escalation will be beneficial for NSCLC treatment. Eurycomalactone (ECL), an active quassinoid isolated from Eurycoma longifolia Jack, has been demonstrated to possess anticancer activity. In this study, we aimed to investigate the effect of ECL on sensitizing NSCLC cells to X-radiation (X-ray) as well as the underlying mechanisms. The results showed that ECL… More >

  • Open Access

    ARTICLE

    IOX-101 Reverses Drug Resistance Through Suppression of Akt/mTOR/NF-κB Signaling in Cancer Stem Cell-Like, Sphere-Forming NSCLC Cell

    Majed Al Fayi*†, Ahmad Alamri*, Prasanna Rajagopalan*†
    Oncology Research, Vol.28, No.2, pp. 177-189, 2020, DOI:10.3727/096504019X15746768080428
    Abstract Drug discovery research to fight lung cancer is incessantly challenged by drug resistance. In this study, we used drug-resistant lung cancer stem like cells (A549-CS) to compare the efficacy of standard drugs like cisplatin (DDP) and gemcitabine (GEM) with a novel arylidene derivative IOX-101. A549-CS was derived from regular A549 cells by growing in special media. Resistance proteins were detected using Western blotting. Cell proliferations were assessed by MTT assay. Cytokine release was enumerated using enzyme-linked immunosorbent assay. The effect of drugs on apoptosis and cell cycle was studied with flow cytometry protocols. Apoptosis-related proteins, caspases, and other signaling protein… More >

  • Open Access

    ARTICLE

    RPSAP52 lncRNA Inhibits p21Waf1/CIP Expression by Interacting With the RNA Binding Protein HuR

    Daniela D’Angelo*, Claudio Arra, Alfredo Fusco*
    Oncology Research, Vol.28, No.2, pp. 191-201, 2020, DOI:10.3727/096504019X15761465603129
    Abstract Long noncoding RNAs have been recently demonstrated to have an important role in fundamental biological processes, and their deregulated expression has been found in several human neoplasias. Our group has recently reported a drastic overexpression of the long noncoding RNA (lncRNA) RPSAP52 (ribosomal protein SA pseudogene 52) in pituitary adenomas. We have shown that this lncRNA increased cell proliferation by upregulating the expression of the chromatinic proteins HMGA1 and HMGA2, functioning as a competing endogenous RNA (ceRNA) through competitively binding to microRNA-15a (miR-15a), miR-15b, and miR-16. The aim of this work was to identify further mechanisms by which RPSAP52 overexpression… More >

  • Open Access

    ARTICLE

    miRNA-101 Targets TGF-bR1 to Retard the Progression of Oral Squamous Cell Carcinoma

    Yong Wang*, Rui-Zhi Jia*, Shu Diao*, Jun He, Li Jia
    Oncology Research, Vol.28, No.2, pp. 203-212, 2020, DOI:10.3727/096504019X15761480623959
    Abstract Despite the considerable knowledge on the involvement of microRNA-101 (miR-101) in the evolution of oral squamous cell carcinoma (OSCC), the underlying mechanisms remain obscure. In this study, miR-101 expression was markedly downregulated in the OSCC cell lines and tissues. Cell counting kit-8 (CCK-8), ethynyl deoxyuridine (EdU), and colony formation assays showed that miR-101 inhibited the proliferation of OSCC cells. Flow cytometry and caspase 3 activity assays indicated that miR-101 induced OSCC cell apoptosis. Transwell assays demonstrated that this miRNA also repressed OSCC cell migration and invasion. Moreover, tube formation assay showed that miR-101 abated the proangiogenesis of OSCC cells. Dual-luciferase… More >

Share Link

WeChat scan